Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now XETRA - Delayed Quote • EUR GSK plc (GS71.DE) Follow Add holdings 17.12 -0.45 (-2.56%) At close: May 2 at 5:35:38 PM GMT+2 All News Press Releases SEC Filings GSK (LON:GSK) Will Pay A Dividend Of £0.16 The board of GSK plc ( LON:GSK ) has announced that it will pay a dividend on the 10th of July, with investors... GSK PLC (GSK) Q1 2025 Earnings Call Highlights: Strong Specialty Medicines Growth Amid Vaccine ... GSK PLC (GSK) reports a robust 17% increase in specialty medicines sales, while vaccine sales face a 6% decline, impacting overall performance. US risks recession as economy shrinks in tariff war The US risks being thrown into recession by Donald Trump’s trade war as official figures showed the economy shrank during the first three months of the year. GSK Jumps On Solid Earnings, Says It's 'Well Positioned' To Navigate Tariffs GSK stock jumped Wednesday after the British drugmaker said it's "well positioned" to respond if the U.S. levies tariffs on drug imports. GSK (LSE:GSK) Sees First Quarter Sales of £7.5 Billion and Net Income Surge GSK (LSE:GSK) reported a significant improvement in its first-quarter earnings, with sales, net income, and earnings per share all showing promising growth. This announcement coincided with a 5.14% rise in GSK's shares over the past week. Meanwhile, broader market trends have been characterized by volatility, with the major indexes seeing declines following a weak GDP report. Despite these fluctuations, GSK's positive earnings report likely bolstered investor sentiment, helping the company to... Wall Street falls while FTSE 100 regains losses after US economy shrinks The American economy contracted by 0.3% in the first three months of the year amid Donald Trump’s threats of sweeping trade tariffs. Tariff turmoil prompts cloudy forecasts from companies for the year ahead Uncertainty continues to hang over the latest round of financial results and forecasts for companies both big and small as they try to navigate a global trade system severely shaken by a shift in U.S. policy. Tariffs and the stark shift in policy has also shaken consumer and business confidence. The U.S. economy shrank during the first quarter of the year, its first drop in three years. Trending tickers: Super Micro, Starbucks, Snap, GSK and Aston Martin The latest investor updates on stocks that are trending on Wednesday. GSK (GSK) Q1 Earnings Surpass Estimates Glaxo (GSK) delivered earnings and revenue surprises of 4.63% and 0.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock? Drugs giant GSK ‘well positioned’ to absorb potential US tariffs It came as the FTSE 100 giant revealed a rise in sales as weakness in its vaccine division was offset by growth in speciality medicines. GSK Sales, Profit Rise on Boost from HIV, Cancer Drugs GSK’s profit rose on better-than-expected performance of HIV, cancer and asthma treatments, offsetting lower vaccine demand in the U.S. GSK 'well positioned' for potential tariffs after beating forecasts GSK on Wednesday said it was "well positioned" to absorb potential U.S. pharmaceutical tariffs, citing AI-driven cost cuts and dual sourcing for its medicines, but offered few details. The British drugmaker reported stronger-than-expected first-quarter results and reaffirmed its 2025 outlook, sending its shares up 3.8% by 0900 GMT. They were among the top gainers on London's FTSE 100 index, which was up 0.02%. Is GSK plc (GSK) the Best Undervalued UK Stock to Buy Right Now? We recently published a list of the 11 Best Undervalued UK Stocks to Buy Right Now. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other best undervalued UK stocks to buy right now. The UK and Europe’s Performance in Q1 2025 The global markets entered 2025 […] Stocks to watch this week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca Earnings preview of key companies reporting next week and what to look out for. Shingles Vaccine Appears to Lower Dementia Risk Mounting evidence suggests that vaccination against the varicella zoster virus—which causes chickenpox in children and triggers shingles in adults—also protects the brain. Several recent studies suggest that the vaccines reduce the risk of dementia in older adults, but key questions remain, including: How the vaccines might work to stop or delay the condition, and whether the benefit is limited to people of a certain age. The vaccines studied, Zostavax and Shingrix, both appeared to offer protection. Why vaccine makers aren't worried about Trump administration cuts Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting. Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). In June 2024, ACIP postponed a vote on a recommendation for adults aged 50-59 at increased risk for RSV-LRTD until additional data becomes available. The update includes Pfizer Inc.’s (NYSE:PFE) Abrysvo (Respiratory Syncyt UK Becomes First Country To Authorize Blenrep In Two Combo Regimens The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday authorized GSK plc’s (NYSE:GSK) Blenrep. Blenrep is approved for the treatment of adults with multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have received at least one prior therapy, and in combination with pomalidomide plus dexamethasone (BPd) in patients who have received at least one prior therapy including lenalidomide. This U.K. regulatory authorization marks the first Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease --76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evalu Performance Overview Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) Return GS71.DE FTSE 100 (^FTSE) YTD +5.48% +5.18% 1-Year -12.06% +5.19% 3-Year -11.83% +13.94%